Literature DB >> 12371012

Pulmonary arterial hypertension in congenital heart disease.

John T Granton1, Marlene Rabinovitch.   

Abstract

Pulmonary arterial hypertension (PAH) is a recognized complication of congenital systemic to pulmonary arterial cardiac shunts. The prognosis of PAH in this situation is better than primary or other secondary forms of PAH. Our knowledge of the pathophysiology of PAH complicating congenital heart disease has evolved over the past decade. Despite differences in etiology and pathobiology, therapies that have proven successful for primary PAH may benefit this group of patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12371012     DOI: 10.1016/s0733-8651(02)00017-6

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  11 in total

1.  Interpretation of the echocardiographic pressure gradient across a pulmonary artery band in the setting of a univentricular heart.

Authors:  Shane M Tibby; Andrew Durward
Journal:  Intensive Care Med       Date:  2007-10-12       Impact factor: 17.440

2.  An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease.

Authors:  Reda Ibrahim; John T Granton; Sanjay Mehta
Journal:  Can Respir J       Date:  2006 Nov-Dec       Impact factor: 2.409

3.  HLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial cells.

Authors:  Stefania Lenna; Danyelle M Townsend; Filemon K Tan; Bagrat Kapanadze; Malgorzata Markiewicz; Maria Trojanowska; Raffaella Scorza
Journal:  J Immunol       Date:  2010-03-24       Impact factor: 5.422

Review 4.  Drug treatment of pulmonary arterial hypertension: current and future agents.

Authors:  Marius M Hoeper
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  [MRI for therapy planning in patients with atrial septum defects].

Authors:  A Huber; M Prompona; R Kozlik-Feldmann; O Mühling; E Rummeny; M Reiser; D Theisen
Journal:  Radiologe       Date:  2011-01       Impact factor: 0.635

6.  Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.

Authors:  Puja K Mehta; Leo Simpson; Eva K Lee; Teresa A Lyle; Michael E McConnell; Wendy M Book
Journal:  Tex Heart Inst J       Date:  2008

7.  Low dose monocrotaline causes a selective pulmonary vascular lesion in male and female pneumonectomized rats.

Authors:  Daniel J Lachant; David F Meoli; Deborah Haight; Jason A Lyons; Robert F Swarthout; R James White
Journal:  Exp Lung Res       Date:  2018-01-30       Impact factor: 2.459

8.  Lumped-Parameter Circuit Platform for Simulating Typical Cases of Pulmonary Hypertensions from Point of Hemodynamics.

Authors:  Hong Tang; Ziyin Dai; Miao Wang; Binbin Guo; Shunyu Wang; Jiabin Wen; Ting Li
Journal:  J Cardiovasc Transl Res       Date:  2020-01-13       Impact factor: 4.132

9.  Bosentan for increased pulmonary vascular resistance in a patient with single ventricle physiology and a bidirectional Glenn shunt.

Authors:  J K Votava-Smith; G S Perens; J C Alejos
Journal:  Pediatr Cardiol       Date:  2007-06-11       Impact factor: 1.838

10.  Living Donor Liver Transplantation in Biliary Atresia Children with Pulmonary Hypertension.

Authors:  Xiao-Yan Meng; Mi-Yuan Chen; Zhi-Ying Pan; Ye-Feng Lu; Wei Wei; Yu-Gang Lu
Journal:  Int J Med Sci       Date:  2019-08-14       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.